Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label Safety Study of Suprachoroidal Triamcinolone Acetonide Injectable Suspension in Patients With Non-Infectious Uveitis

Next Previous
X
Search
Trial Profile

Open-label Safety Study of Suprachoroidal Triamcinolone Acetonide Injectable Suspension in Patients With Non-Infectious Uveitis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Triamcinolone (Primary)
  • Indications Anterior uveitis; Intermediate uveitis; Panuveitis; Posterior uveitis
  • Focus Adverse reactions; Registrational
  • Acronyms AZALEA
  • Sponsors Clearside Biomedical

    • Most Recent Events

    • 18 Nov 2022 Results of Integrated Analysis of Two Phase 3 Studies(NCT02595398 and NCT03097315) for triamcinolone acetonide injectable suspension for suprachoroidal use in the treatment of macular edema secondary to noninfectious uveitis published in the Ophthalmology and Therapy
    • 01 Jun 2022 Results published in the British Journal of Ophthalmology
    • 05 May 2022 According to a Clearside Biomedical media release, data from the study was presented at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top